Achieve Life Sciences, Inc. (NASDAQ:ACHV) Receives Average Rating of “Moderate Buy” from Brokerages

Shares of Achieve Life Sciences, Inc. (NASDAQ:ACHV) have been assigned an average rating of “Moderate Buy” from the five analysts that are presently covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, three have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month target price among brokerages that have updated their coverage on the stock in the last year is $15.50.

Several equities analysts have weighed in on the company. HC Wainwright reaffirmed a “buy” rating and set a $12.00 target price on shares of Achieve Life Sciences in a research note on Wednesday, March 25th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Achieve Life Sciences in a research report on Monday, December 29th.

Institutional Trading of Achieve Life Sciences

Institutional investors have recently bought and sold shares of the company. ADAR1 Capital Management LLC increased its stake in shares of Achieve Life Sciences by 10.7% during the 3rd quarter. ADAR1 Capital Management LLC now owns 47,800 shares of the biopharmaceutical company’s stock worth $151,000 after purchasing an additional 4,627 shares during the last quarter. Bank of America Corp DE lifted its stake in shares of Achieve Life Sciences by 39.9% in the 2nd quarter. Bank of America Corp DE now owns 33,731 shares of the biopharmaceutical company’s stock valued at $76,000 after purchasing an additional 9,617 shares during the last quarter. Robertson Stephens Wealth Management LLC lifted its stake in shares of Achieve Life Sciences by 100.0% in the 4th quarter. Robertson Stephens Wealth Management LLC now owns 20,000 shares of the biopharmaceutical company’s stock valued at $99,000 after purchasing an additional 10,000 shares during the last quarter. AQR Capital Management LLC bought a new stake in Achieve Life Sciences in the first quarter worth $32,000. Finally, Manchester Financial Inc. boosted its holdings in Achieve Life Sciences by 26.6% in the fourth quarter. Manchester Financial Inc. now owns 59,084 shares of the biopharmaceutical company’s stock worth $294,000 after purchasing an additional 12,410 shares in the last quarter. Institutional investors and hedge funds own 33.52% of the company’s stock.

Achieve Life Sciences News Roundup

Here are the key news stories impacting Achieve Life Sciences this week:

• Positive Sentiment: HC Wainwright reiterated a Buy rating and $12 target while materially boosting long‑range EPS forecasts (FY2029 and FY2030 upgrades), signaling confidence in ACHV’s longer‑term commercial potential. Achieve Life Sciences (NASDAQ:ACHV) Earns Buy Rating from HC Wainwright
• Positive Sentiment: A peer‑reviewed publication linked cytisinicline’s receptor profile to low nausea and favorable tolerability, a clinical differentiator that could support uptake if approved. Publication in Nicotine & Tobacco Research
• Positive Sentiment: Analysts and commentators are highlighting the upcoming PDUFA (June 20, 2026) and planned Phase 3 vaping cessation trial (ORCA‑V2 in 1H 2026) as major value catalysts toward a possible 1H‑2027 commercial launch if approved. Achieve Life Sciences: Maintaining ‘Buy’ On Upcoming PDUFA…
• Positive Sentiment: Unusually large retail/institutional activity in call options suggests speculative bullish positioning ahead of the PDUFA and other near‑term catalysts. Investors Purchase Large Volume of Call Options on Achieve Life Sciences
• Neutral Sentiment: HC Wainwright also updated quarter‑by‑quarter 2026 EPS estimates (small quarterly losses expected) while keeping the Buy stance — important for modeling near‑term cash needs but not a directional change to the thesis. MarketBeat ACHV coverage
• Neutral Sentiment: The company’s Q4 2025 transcript and summary show a modest EPS miss and operational detail; useful for context on execution but not a game‑changer versus the upcoming FDA decision. Q4 2025 earnings call transcript Q4 2025 Earnings Call Summary
• Negative Sentiment: Mixed analyst revisions include downgrades to mid‑term EPS (HC Wainwright trimmed FY2027 and FY2028; Zacks cut FY2026/FY2027), which raises uncertainty on near‑term profitability and could pressure the stock ahead of the PDUFA. Market analyst estimate changes

Achieve Life Sciences Price Performance

ACHV stock opened at $2.65 on Monday. Achieve Life Sciences has a one year low of $1.84 and a one year high of $6.03. The firm has a 50-day moving average of $4.31 and a two-hundred day moving average of $4.30. The firm has a market capitalization of $141.06 million, a PE ratio of -2.04 and a beta of 1.81. The company has a current ratio of 4.39, a quick ratio of 4.39 and a debt-to-equity ratio of 0.52.

Achieve Life Sciences (NASDAQ:ACHV) last released its earnings results on Tuesday, March 24th. The biopharmaceutical company reported ($0.28) earnings per share for the quarter, missing the consensus estimate of ($0.27) by ($0.01). On average, analysts forecast that Achieve Life Sciences will post -1.17 earnings per share for the current year.

Achieve Life Sciences Company Profile

Achieve Life Sciences, Inc (NASDAQ: ACHV) is a clinical-stage biotechnology company dedicated to the development and commercialization of cytisinicline, a plant-derived alkaloid for smoking cessation. The company’s mission is to offer a novel, evidence-based therapy that addresses the global need for effective and well-tolerated smoking cessation options. Achieve focuses its efforts on advancing the clinical profile of cytisinicline through rigorous development programs and regulatory engagement.

Cytisinicline (formerly marketed as Tabex® in Europe) acts as a nicotinic acetylcholine receptor partial agonist, helping reduce withdrawal symptoms and nicotine cravings.